University Of Texas/Texas Am Investment Management Co's Form 4/A amendment
AmendedRein Therapeutics, Inc. (RNTX) · filed May 14, 2024
- Accession no.
- 0001019231-24-000023
- Filed
- May 14, 2024
- Trade date
- May 1, 2024
- Filing delay
- 13 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 1, 2024
This filing lists 16 non-derivative transactions. It carries over 8 transactions from the original filing that it did not restate. Open-market sales total $139.1K. It was filed 13 days after the trade.
This amendment restates part of 0001019231-24-000022 (filed May 1, 2024). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| University Of Texas/Texas Am Investment Management CoCIK 0001019231 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2024 | Common Stock | SSaleDisposed | −3,100 | $4.10 | −$12,710 | 1,807,357 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −100 | $4.11 | −$411 | 1,807,257 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −1,750 | $4.12 | −$7,210 | 1,805,507 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −380 | $4.13 | −$1,569.4 | 1,805,127 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −1,600 | $4.15 | −$6,640 | 1,803,527 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −670 | $4.15 | −$2,780.5 | 1,802,857 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −400 | $4.18 | −$1,672 | 1,802,457 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −7,923 | $4.25 | −$33,672.75 | 1,794,534 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −310 | $4.26 | −$1,320.6 | 1,794,224 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −317 | $4.27 | −$1,353.59 | 1,793,907 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −100 | $4.27 | −$427 | 1,793,807 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −200 | $4.28 | −$856 | 1,793,607 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −337 | $4.28 | −$1,442.36 | 1,793,270 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −200 | $4.29 | −$858 | 1,793,070 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −2,903 | $4.29 | −$12,453.87 | 1,790,167 | Direct | |
| May 1, 2024 | Common Stock | SSaleDisposed | −25 | $4.32 | −$108 | 1,790,142 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001019231-24-000022 (filed May 1, 2024).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 29, 2024 | Common Stock | SSaleDisposed | −6,680 | $4.92 | −$32,865.6 | 1,803,777 | Direct | |
| Apr 29, 2024 | Common Stock | SSaleDisposed | −274 | $4.93 | −$1,350.82 | 1,803,503 | Direct | |
| Apr 29, 2024 | Common Stock | SSaleDisposed | −100 | $4.94 | −$494 | 1,803,403 | Direct | |
| Apr 29, 2024 | Common Stock | SSaleDisposed | −3,231 | $5.00 | −$16,155 | 1,800,172 | Direct | |
| Apr 29, 2024 | Common Stock | SSaleDisposed | −13 | $5.01 | −$65.13 | 1,800,159 | Direct | |
| Apr 29, 2024 | Common Stock | SSaleDisposed | −448 | $5.03 | −$2,253.44 | 1,799,711 | Direct | |
| Apr 30, 2024 | Common Stock | SSaleDisposed | −45 | $4.95 | −$222.75 | 1,799,666 | Direct | |
| Apr 30, 2024 | Common Stock | SSaleDisposed | −45 | $5.00 | −$225 | 1,799,621 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.